GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » PB Ratio

Knight Therapeutics (TSX:GUD) PB Ratio : 0.68 (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-14), Knight Therapeutics's share price is C$5.20. Knight Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was C$7.66. Hence, Knight Therapeutics's PB Ratio of today is 0.68.

Good Sign:

Knight Therapeutics Inc stock PB Ratio (=0.67) is close to 1-year low of 0.66

The historical rank and industry rank for Knight Therapeutics's PB Ratio or its related term are showing as below:

TSX:GUD' s PB Ratio Range Over the Past 10 Years
Min: 0.56   Med: 1.07   Max: 1.74
Current: 0.68

During the past 11 years, Knight Therapeutics's highest PB Ratio was 1.74. The lowest was 0.56. And the median was 1.07.

TSX:GUD's PB Ratio is ranked better than
88.94% of 940 companies
in the Drug Manufacturers industry
Industry Median: 2.075 vs TSX:GUD: 0.68

During the past 12 months, Knight Therapeutics's average Book Value Per Share Growth Rate was -1.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 2.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 2.30% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Knight Therapeutics was 9.60% per year. The lowest was -4.50% per year. And the median was 2.70% per year.

Back to Basics: PB Ratio


Knight Therapeutics PB Ratio Historical Data

The historical data trend for Knight Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics PB Ratio Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.27 0.79 0.74 0.70 0.70

Knight Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.70 0.70 0.75 0.77

Competitive Comparison of Knight Therapeutics's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's PB Ratio falls into.



Knight Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Knight Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=5.20/7.664
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Knight Therapeutics  (TSX:GUD) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Knight Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
Executives
Sime Armoyan 10% Security Holder
Samira Sakhia Director, Senior Officer
Amal Khouri Senior Officer
Jonathan Ross Goodman Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande Director
Janice Jean Murray Director
Nicolas Sujoy Director
Long Zone Holdings Inc. 10% Security Holder
Arvind Utchanah Senior Officer
Michael Joseph Tremblay Director
James Gale Director
Michael Dehn Director, Senior Officer
Andrew Moor Senior Officer
Patrick Mcclymont Senior Officer
Kevin Drew Nabholz Director

Knight Therapeutics Headlines

No Headlines